SCHEMBL20152352

SCHEMBL20152352

COc1ccc(C(=O)N2C3CC2CN(C(C)(C)C)C3)cc1F

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CPS1 P31327 1/20 0.48
HTT P42858 2/20 0.48
LMNA P02545 2/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48
RET P07949 2/20 0.46
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 3/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KCNQ3 O43525 1/20 0.41
KCNQ2 O43526 1/20 0.41
PDE5A O76074 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18713099 0.86 HTT (0.51) CPS1HTTLMNAMAPK1RAB9A
SCHEMBL20152357 0.86 RET (0.46) RAB9ARETTAS1R3TAS1R1ALDH1A1
SCHEMBL20152351 0.84 RET (0.43) HTTLMNARETALDH1A1KMT2A
SCHEMBL18389842 0.83 CPS1 (0.48) CPS1HTTLMNAMAPK1RAB9A
SCHEMBL20070594 0.83 CPS1 (0.48) CPS1HTTLMNAMAPK1RAB9A
SCHEMBL18389840 0.81 HTT (0.51) CPS1HTTLMNAMAPK1RAB9A
SCHEMBL20152355 0.73 ALDH1A1 (0.46) HTTLMNARETALDH1A1KMT2A
SCHEMBL20152356 0.73 HPGD (0.54) MAPK1RAB9ARETALDH1A1KMT2A
SCHEMBL20152354 0.73 KMT2A (0.45) CPS1HTTLMNARAB9ARET
SCHEMBL20160469 0.72 RET (0.46) RETKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ELI LILLY AND COMPANY (US) 2020-02-11 US disclosed
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2019-06-20 US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF CPS1 4470/4885HTT 3519/4885LMNA 2631/4885
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF CPS1 4470/4885HTT 3519/4885LMNA 2631/4885
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF CPS1 4470/4885HTT 3519/4885LMNA 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.